NFE2L2 and systemic sclerosis: Evidence from both in vivo (SSc animal models) and in vitro (skin biopsies from SSc patients) studies indicates that nuclear factor-erythroid 2-related factor 2 (Nrf2) activation confers both antifibrotic and anti-inflammatory benefits [139].